LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Amgen Inc

Chiusa

SettoreSettore sanitario

277.02 -0.75

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

275.38

Massimo

281.19

Metriche Chiave

By Trading Economics

Entrata

1.1B

1.7B

Vendite

-937M

8.1B

P/E

Media del settore

26.375

50.291

EPS

4.9

Rendimento da dividendi

3.29

Margine di Profitto

21.23

Dipendenti

28,000

EBITDA

-1.7B

1.2B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+17.07% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.29%

2.40%

Utili prossimi

5 ago 2025

Prossima data del Dividendo

5 set 2025

Prossima data del' Ex Dividendo

15 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-2.5B

156B

Apertura precedente

277.77

Chiusura precedente

277.02

Notizie sul Sentiment di mercato

By Acuity

39%

61%

121 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Amgen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 giu 2025, 19:24 UTC

I principali Market Mover

Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update

23 giu 2025, 19:07 UTC

I principali Market Mover

Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial

1 mag 2025, 20:17 UTC

Utili

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

28 mag 2025, 18:09 UTC

Utili

Heart Disease Could Be a Goner When These New -2-

28 mag 2025, 18:09 UTC

Utili

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

19 mag 2025, 16:13 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

1 mag 2025, 20:01 UTC

Utili

Amgen: FY25 Share Repurchases Not to Exceed $500M

1 mag 2025, 20:01 UTC

Utili

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen Sees FY25 Capital Expenditures About $2.3B

1 mag 2025, 20:01 UTC

Utili

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Repatha Sales $656M >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q EVENITY Sales $442M >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Net $1.73B >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Adj EPS $4.90 >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q EPS $3.20 >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Rev $8.15B >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Rev $8.1B >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Net $1.73B >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen Sees FY EPS $12.21-EPS $13.46 >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1 mag 2025, 20:01 UTC

Utili

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

Confronto tra pari

Modifica del prezzo

Amgen Inc Previsione

Obiettivo di Prezzo

By TipRanks

17.07% in crescita

Previsioni per 12 mesi

Media 326.76 USD  17.07%

Alto 400 USD

Basso 252 USD

Basato su 22 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amgen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

22 ratings

11

Acquista

10

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

270.44 / 276.44Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

121 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.